Dark

Check out our Dark Pool Levels

RDN
Radian Group Inc.
stock NYSE

At Close

Sep 21, 2026 3:59:50 PM EDT

34.35USD-1.899%(-0.66)863,105

29.89Bid 34.36Ask 4.47Spread

Pre-market

Sep 18, 2026 9:29:59 AM EDT

34.85USD-0.443%(-0.16)0

After-hours

Sep 21, 2026 4:10:30 PM EDT

34.32USD-0.073%(-0.03)1

OverviewOptionsHistoricalExchangesShortsTrends

RDN Reddit Mentions

Subreddits

Limit Labels Price

We have sentiment values and mention counts going back to 2017. The complete data set is available via the API.

Take me to the API

RDN Specific Mentions

As of Sep 21, 2026 7:59:41 PM EDT (1 min. ago)

Includes all comments and posts. Mentions per user per ticker capped at one per hour.

2 days ago • u/HuckSauce • r/stocks • boston_scientific_peaked_at_105_last_november_it • C

I haven’t seen anyone mention the key concern that caused the sector to sell off, GLP-1’s.
There is some concern that minimally invasive tech forecasted demand for chronic conditions could be negatively impacted due to a reduction in the obese population.
BSC was particularly negatively impacted due to Watchman having both a competitor (Abbott) come into the space and results from a clinical trial comparing it to blood thinners that wasn’t as enticing of data as expected.
Last is their PFA tech (Fara) which is the hottest category in MedTech is losing market share to competition.
In summary BSCI was valued at a premium by Wallstreet because they had the only real offering in two high-growth categories (LAAC - Watchman, PFA - Fara), and since that point, the market share, growth rate, and TAM are in question.
ICE, RDN, and IVL technologies are the keys to watch moving forward.

2 days ago • u/HuckSauce • r/stocks • boston_scientific_peaked_at_105_last_november_it • C

I haven’t seen anyone mention the key concern that caused the sector to sell off, GLP-1’s.
There is some concern that minimally invasive tech forecasted demand for chronic conditions could be negatively impacted due to a reduction in the obese population.
BSC was particularly negatively impacted due to Watchman having both a competitor (Abbott) come into the space and results from a clinical trial comparing it to blood thinners that wasn’t as enticing of data as expected.
Last is their PFA tech (Fara) which is the hottest category in MedTech is losing market share to competition.
In summary BSCI was valued at a premium by Wallstreet because they had the only real offering in two high-growth categories (LAAC - Watchman, PFA - Fara), and since that point, the market share, growth rate, and TAM are in question.
ICE, RDN, and IVL technologies are the keys to watch moving forward.

Share